FDA Inspection
Brio Pharmaceuticals IncBrio Pharmaceuticals Inc – FDA Inspection, Feb 27, 2026
Record Details
This FDA Inspection record concerns Brio Pharmaceuticals Inc, with an inspection on February 27, 2026, issued by the Dallas District Office, covering human drugs.
View Company Profile
ID · 215855d7-cef6-4306-9ed7-1cf6d2c8aaba
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1304746
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
2- 21 CFR 211.166(a)Written program not followed
- 21 CFR 211.22(d)Procedures not in writing, fully followed
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Brio Pharmaceuticals Inc
10| Date | Classification | Office | Project area |
|---|---|---|---|
| June 19, 2026 | Not classified | Dallas District Office | |
| July 11, 2019 | VAI | Center for Drug Evaluation and Research | Generic Drug Evaluation |
| October 3, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 26, 2017 | Not classified | Dallas District Office | Drug Quality Assurance |
| June 1, 2015 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Brio Pharmaceuticals Inc
- FDA Inspection 1323564 - 2026-06-19
- FDA Inspection 1096432 - 2019-07-11
- FDA Inspection 1067624 - 2018-10-03
- FDA Inspection 1011466 - 2017-04-26
- FDA Inspection 929358 - 2015-06-01
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.